Medical Advocates

Etravirine (Intelence/TMC125)
  Journal Papers, Abstracts, and Commentaries
 
In Vitro Data
Animal Studies
General Reports        
Pharmacokinetics
Safety
Virology
Resistance
Drug/Drug Interaction
s
Diagnostics/Monitoring
Efficacy
Adverse Events
Therapeutic Strategies
Drug Comparison Studies

Economics






 
 

Etravirine Main Page Main New/Newsworthy  Home Page      

Last Update:  April 07, 2017 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

In Vitro Data
 

 

Interaction potential of etravirine with drug transporters assessed in vitro.
Zembruski NC, Haefeli WE, Weiss J.

Antimicrob Agents Chemother
. 2010 Dec 28.
Abstract

In Situ_ FT-IR Investigation of Etravirine Speciation in Pores of SBA-15 Ordered Mesoporous Silica Material upon Contact with Water.
Mellaerts R, Fayad EJ, Van den Mooter G, et al
Mol Pharm
. 2012 Dec 19
Abstract

T
Activity of Etravirine on Different HIV Type 1 Subtypes: In Vitro Susceptibility in Treatment-Naive Patients and Week 48 Pooled DUET Study Data.
Vingerhoets J, Azijn H, Tambuyzer L, Dierynck I,
et al 
AIDS Res Hum Retroviruses
. 2010 May 27

Abstract

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro
selection experiments.

Vingerhoets J, Azijn H, Fransen E, et al
J Virol. 2005 Oct;79(20):12773-82.
Abstract


Animal Studies
 

 
Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.
Blakney AK, Jiang Y, Whittington D, Woodrow KA.
J Chromatogr B Analyt Technol Biomed Life
Sc
i. 2016 May 2;1025:110-118.
Abstract

Effects of Etravirine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Rats.
John J, John M, Wu L, Hsiao C,  et al
Br J Pharmacol
. 2012 Dec 5.

Abstract


General Reports
 

 
Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.
Green B, Crauwels H, Kakuda TN, et al
Clin Pharmacokinet
. 2016 Sep 24
Abstract

Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.
Kwon OK, Kim SS, Rhee JE, et al

Virol J
. 2015 Apr 9;12(1):53.
Paper

Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity.
Agneskog E, Nowak P, Maijgren Steffensson C, et al

PLoS One
. 2014 Jul 7;9(7):e101508.
Paper

Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
Tudor-Williams G, Cahn P, Chokephaibulkit K, et al
HIV Med
. 2014 Mar 3.
Abstract

Influence of adding etravirine on complexity index and patients' perceived complexity.
Calvo-Cidoncha E, González-Bueno J, Almeida-González CV, Morillo-Verdugo R.

J Clin Pharm Ther
. 2013 Dec 23

Abstract

Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network.
Gebo K, Voss C, Mrus J, HIV Research Network.
AIDS Res Treat. 2013;2013:492831
Abstract

Etravirine in CSF is highly protein bound.
Nguyen A, Rossi S, Croteau D, et al
J Antimicrob Chemother
. 2013 Jan 20
.
Abstract

Etravirine concentrations in seminal plasma in HIV-infected patients.
Tiraboschi J, Niubo J, Ferrer E,  et al
J Int AIDS Soc
. 2012 Nov 11;15(6):18341.
Abstract

Etravirine Concentrations in the Cervico-Vaginal Compartment in HIV-1 infected Women receiving Etravirine-containing antiretroviral therapy: DIVA 02 study.
Clavel C, Peytavin G, Tubiana R,  et al
Antimicrob Agents Chemother. 2012 Apr 23.
Abstract

Etravirine concentrations in CSF in HIV-infected patients.
Tiraboschi JM, Niubo J, Vila A, et al
J Antimicrob Chemother. 2012 Feb 22
Abstract

Connection Domain Mutations in HIV-1 Reverse Transcriptase do not Impact Etravirine Susceptibility and Virologic Responses to Etravirine-containing Regimens.
Gupta S, Vingerhoets J, Fransen S, et al.

Antimicrob Agents Chemother
. 2011 Apr
Abstract

A randomized crossover study to compare efavirenz and etravirine treatment.
Nguyen A, Calmy A, Delhumeau C,  et al
AIDS
. 2010 Nov 11.
Abstract

Etravirine in the Treatment of HIV-1: A Clinical Overview for Healthcare Professionals.
Yeni P, Mills A, Peeters M, Vingerhoets J, et al
Curr HIV Res
. 2010 Oct 13.
Abstract

Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance.
Towner WJ, Cassetti I, Domingo P,  et al
Antivir Ther
. 2010;15(6):803-16.
Abstract

Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance.
Towner WJ, Cassetti I, Domingo P,  et al
Antivir Ther.
2010;15(6):803-16.
Abstract

Physicochemical properties of the amorphous drug, cast films, and spray dried powders \to predict formulation probability of success for solid dispersions: Etravirine.
Weuts I, Van Dycke F, Voorspoels J
J Pharm Sci. 2010 Jun 22
Abstract

Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug Design.
Lansdon EB, Brendza KM, Hung M, et al

J Med Chem
. 2010 May 3
Abstract

Profile of etravirine for the treatment of HIV infection.
Tseng A, Macarthur RD. 
Ther Clin Risk Manag. 2010 Feb 2;6:49-58.
Abstract

Etravirine: A novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection.
Elsayed RK, Caldwell DJ.

Am J Health Syst Pharm
. 2010 Feb 1;67(3):193-205.
Abstract

Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
Marcelin AG, Flandre P, Descamps D, et al

Antimicrob Agents Chemother
. 2010 Jan;54(1):72-7
Abstract
 
Chemical characteristics, mechanism of action and antiviral activity of etravirine.
García FG, Estévez MA, Suay VG. 
Enferm Infecc Microbiol Clin. 2009 Dec;27S2:2-5.
Abstract
 
Etravirine in special populations
Santos Gil ID.
Enferm Infecc Microbiol Clin. 2009 Dec;27S2:40-45
Abstract
 
Role of etravirine in combination antiretroviral therapy.
Domingo P.

Enferm Infecc Microbiol Clin
. 2009 Dec;27S2:46-51.
Abstract

New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
Hughes CA, Robinson L, Tseng A, Macarthur RD.
Expert Opin Pharmacother. 2009 Aug 13.
Abstract

Etravirine: new drug. Multidrug-resistant HIV: another option.
[No authors listed]  
Prescrire Int. 2009 Jun;18(101):102-3.
Abstract

Etravirine: A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS, Youssef-Bessler M. 

Clin Ther
. 2009 Apr;31(4):692-704.
Abstract

Etravirine, a Next-Generation Nonnucleoside Reverse-Transcriptase Inhibitor.
Johnson LB, Saravolatz LD.

Clin Infect Dis
. 2009 Mar 10
Abstract

Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
Fulco PP, McNicholl IR.
Pharmacotherapy. 2009 Mar;29(3):281-94
Abstract
 
Raltegravir and Etravirine Are Active against HIV Type 1 Group O.
Briz V, Garrido C, Poveda E, et al
 
AIDS Res Hum Retroviruses
. 2009
Abstract
 
Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes.
Covens K, Kabeya K, Schrooten Y, et al
J Clin Virol. 2009 Feb 21.

Abstract
 
Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.
Jayaweera DT, Espinoza L, Castro J
.
Expert Opin Pharmacother.
2008 Dec;9(17):3083-94.
Abstract
 
Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
Schöller-Gyüre M, Boffito M, et al

Pharmacotherapy.
2008 Oct;28(10):1215-22.
Abstract
 
Etravirine for the treatment of HIV infection.
Seminari E, Castagna A, Lazzarin A. 

Expert Rev Anti Infect Ther.
2008 Aug;6(4):427-33.
Abstract

Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?
Scott C, Grover D, Nelson M.
 
AIDS. 2008 May 11;22(8):989-90.
Abstract
 

Etravirine Has No Effect on QT and Corrected QT Interval in HIV-Negative Volunteers (June).
Peeters M, Janssen K, Kakuda TN, et al

Ann Pharmacother.
2008 Apr 29
Abstract
 
Etravirine.
Knoll BM, Vento S, Temesgen Z. 

Drugs Today
(Barc). 2008 Jan;44(1):23-33
Abstract

FULL-TEXT ARTICLE
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
Andries K, Azijn H, Thielemans T, et al
Antimicrob Agents Chemother. 2004 Dec;48(12):4680-6.
Paper

Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and
effective against wild-type and drug-resistant HIV-1 variants.
Das K, Clark AD Jr, Lewi PJ, et al

J Med Chem. 2004 May 6;47(10):2550-60.
Abstract

Pharmacokinetics
 

 
Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women.
Ramgopal M, Osiyemi O, Zorrilla C, et al
J Acquir Immune Defic Syndr. 2016 May 6.
Abstract

Comparison of population pharmacokinetics based on steady-state assumption versus electronically monitored adherence to lopinavir, atazanavir, efavirenz, and etravirine: A retrospective study.
Aline F, Aurélie R, Matthias C, et al
Ther Drug Monit
. 2016 Mar 1.
Abstract

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients.
Orrell C, Felizarta F, Nell A,  et al
AIDS Res Treat. 2015;2015:938628.

Paper

Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies.
Kakuda TN, Berckmans C, De Smedt G,  et al
Int J Clin Pharmacol Ther. 2013 Aug 7
Abstract

Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-Naïve Patients.
Di Perri G, Green B, Morrish G, , et al
HIV Clin Trials
. 2013 May-Jun;14(3):92-8.
Abstract

Steady-State Pharmacokinetics of Etravirine and Lopinavir/Ritonavir Melt Extrusion Formulation, Alone and in Combination, in Healthy HIV-Negative Volunteers.
Schöller-Gyüre M, Kakuda TN, et al
J Clin Pharmacol
. 2013 Feb;53(2):202-10
Abstract

Pharmacokinetics of Maraviroc, Raltegravir, Darunavir, and Etravirine in the Semen of HIV-Infected Men.
Antoniou T, Hasan S, Loutfy MR,  et al

J Acquir Immune Defic Syndr
. 2013 Feb 1;62(2):e58-60.
Abstract

Pharmacokinetics and Short-Term Safety of Etravirine in Combination With Fluconazole or Voriconazole in HIV-Negative Volunteers.
Kakuda TN, Van Solingen-Ristea R, Aharchi F, et al
J Clin Pharmacol. 2013 Jan;53(1):41-50.|
Abstract

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals
Lubomirov R, Arab-Alameddine M, Rotger M, et al
Pharmacogenet Genomics. 2012 Oct 29.
Abstract

Steady-State Pharmacokinetics of Etravirine and Lopinavir/Ritonavir Melt Extrusion Formulation, Alone and in Combination, in Healthy HIV-Negative Volunteers.
Schöller-Gyüre M, Kakuda TN, et al
J Clin Pharmacol. 2012 May 1.
Abstract

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.
Kakuda T, Sekar V, Vis P, et al

AIDS Res Treat
. 2012;2012:186987
Abstract

FULL-TEXT ARTICLE
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
Kakuda T,  Sekar V,  Vis P, et al
AIDS Research and Treatmen
t Vol 2012  Art ID 186987|
Paoer

Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents.
Königs C, Feiterna-Sperling C, Esposito S,  et al
AIDS
. 2011 Dec 7
Abstract

Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients.
Gutiérrez-Valencia A, Martin-Peña R, et al

J Antimicrob Chemother
. 2011 Dec 21
Abstract

Darunavir, Ritonavir and Etravirine Pharmacokinetics in the Cervicovaginal Fluid and Blood Plasma of HIV-Infected Women
Patterson K, Jennings S, Falcon R,  et al

Antimicrob Agents Chemother
. 2010 Dec 20
Abstract


Pharmacokinetic evaluation of etravirine.
Dickinson L, Khoo S, Back D.
Expert Opin Dr
ug Metab Toxicol. 2010 Dec;6(12):1575-1585.
Abstract

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
Barrail-Tran A, Yazdanpanah Y, Goldwirt L,  et al

AIDS
. 2010 Oct 23;24(16):2581-3.
Abstract

Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients.
Kakuda TN, Wade JR, Snoeck E,
 et al
Clin Pharmacol Ther
. 2010 Sep 29.
Abstract

Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
DeJesus E, Lalezari JP, Osiyemi OO,
 et al
Antivir Ther
. 2010;15(5):711-20.
Abstract

Clinical pharmacokinetics and pharmacodynamics of etravirine.
Schöller-Gyüre M, Kakuda TN, Raoof A, et al 
Clin Pharmacokinet. 2009;48(9):561-74
Abstract

Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers.
Boffito M, Jackson A, Lamorde M, et al

J Acquir Immune Defic Syndr
. 2009 Jul 17
Abstract

Single- and multiple-dose pharmacokinetics of etravirine administered as two different  formulations in HIV-1-infected patients.
Kakuda TN, Schöller-Gyüre M,
 
Antivir Ther.
2008;13(5):655-61.
Abstract

A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-volunteers.
Schöller-Gyüre M, Kakuda TN, De Smedt G, et al
Br J Clin Pharmacol. 2008 May 19
Abstract

Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of Methadone and TMC125 in HIV-Negative Volunteers.
Schöller-Gyüre M, van den Brink W, et al
J Clin Pharmacol. 2008 Jan 14
Abstract


Safety
 

 

 

Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.
Floris-Moore MA, Mollan K, Wilkin AM, et al
Antivir Ther. 2015 Aug 11.
Abstract

Efficacy and Safety Outcomes Among Treatment-Experienced Men and Women Treated with  Etravirine in GRACE (Gender, Race AND Clinical Experience).
Hodder S, Jayaweera D, Mrus JM,  et al
AIDS Res Hum Retroviruses. 2011 Dec 29.
Abstract

Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
Clotet B, Clumeck N, Katlama C, et al

J Antimicrob Chemother
. 2010 Aug 27
Abstract

A Review of the Safety and Tolerability Profile of the Next-Generation NNRTI Etravirine.
Grinsztejn B, Di Perri G, Towner W,
et al
AIDS Res Hum Retroviruses
. 2010 Jul 12.
Abstract

Safety and tolerability of etravirine.
Portilla J.
 
Enferm Infecc Microbiol Clin
. 2009 Dec;27S2:21-26

Abstract


Virology
 

 

 

Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients.
Calcagno A, Marinaro L, Nozza S,  et al

Antiviral Res
. 2014 May 23.
Abstract

Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.
Clumeck N, Cahn P, Molina JM,
et al
Int J STD AIDS
. 2010 Nov;21(11):738-40.
Abstract


Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis
of DUET-1 and -2.

Trottier B, Di Perri G, Madruga JV,
 et al
HIV Clin Trials
. 2010 Jul-Aug;11(4):175-85

Abstract

Resistance
 

 
Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
Picchio GR, Rimsky LT, Van Eygen V,  et al

Antivir Ther
. 2014 Apr 4.

Abstract

Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
Geretti AM, Conibear T, Hill A,  et al
J Antimicrob Chemother. 2013 Nov 27
Abstract

The Connection Domain Mutation N348I in HIV-1 Reverse Transcriptase Enhances Resistance to Etravirine and Rilpivirine but Restricts the Emergence of the E138K Resistance Mutation by Diminishing Viral Replication Capacity.
Xu HT, Colby-Germinario SP, Oliveira M,  et al
J Virol
. 2013 Nov 13.
Abstract

Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.
Fofana DB, Soulie C, Maiga AI, et al
J Antimicrob Chemother
. 2013 Jul 5.
Abstract

Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: The VOLTART cohort study in Côte d'Ivoire, West Africa.
Messou E, Chaix ML, Gabillard D, et al
J Acquir Immune Defic Syndr
. 2013 Jun 21
Abstract

Replication fitness of multiple NNRTI-resistant HIV-1 variants in the presence of etravirine measured by 454 deep sequencing.
Brumme CJ, Huber KD, Dong W, et al
J Viro
l
. 2013 May 29
Abstract

The Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase and their Interactions with the M184I Mutation in Defining Patterns of Resistance to the Non-Nucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine.
Xu HT, Colby-Germinario SP, Asahchop EL, et al
Antimicrob Agents Chemother
. 2013 Apr 22.
Abstract

Evaluation of etravirine resistance in clinical samples by a simple phenotypic Test.
Agneskog E, Nowak P, Källander CF, Sönnerborg A.
J Med Viro
l
. 2013 Apr;85(4):703-8.
Abstract

FULL-TEXT ARTICLE
Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.
Aghokeng AF, Kouanfack C, Eymard-Duvernay S,  et al
J Int AIDS Soc. 2013 Jan 31;16:18004.
Paper

Distinct resistance patterns to etravirine and rilpivirine in viruses containing nnrti mutations at baseline.
Asahchop EL, Wainberg MA, Oliveira M, et al
AIDS
. 2012 Dec 19.
Abstract

Genotypic susceptibility to etravirine-assessment in a population of NNRTI-experienced patients.
Piñeiro C, Xerinda S, Figueiredo C,  et al
J Int AIDS
Soc
. 2012 Nov 11;
Abstract

FULL-TEXT ARTICLE
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Balamane M, Varghese V, Melikian GL,  et al
Antimicrob Agents Chemother
. 2012 Aug;56(8):4522-4
Paper

Susceptibility to Etravirine of HIV-1 subtype C isolates from Nevirapine/Efavirenz-experienced patients: comparative interpretation of ANRS and STANFORD algorithms.
Fleury HJ, Anquetil D, Deshpande A, et al
AIDS Res Hum Retroviruses. 2012 Apr 20.
Abstract

Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.
Pereira-Vaz J, Duque V, Pereira B, et al
J Med Virol
. 2012 Apr;84(4):551-4.
Abstract

Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: Comparison between subtype B and non-B genetic variants.
Pereira-Vaz J, Duque V, Pereira B, et al
 J Med Virol. 2012 Apr;84(4):551
Abstract

Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG, Descamps D, Tamalet C,  et al

Antivir Ther
. 2012;17(1):119-123.
Abstract

Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside
reverse transcriptase inhibitor-based regimens.
Bunupuradah T, Ananworanich J, Chetchotisakd P,  et al
Antivir Ther. 2011;16(7):1113-21
Abstract

Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.
Hu Z, Kuritzkes DR.
J Virol. 2011 Aug 17.
Abstract

Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine.
Tambuyzer L, Nijs S, Daems B, Picchio G, Vingerhoets J.
J Acquir Immune Defic Syndr. 2011 Jun 2
Abstract

Prevalence of Susceptibility to Etravirine by Genotype and Phenotype in Samples Received for Routine HIV-1 Resistance Testing in the USA.
Picchio G, Vingerhoets J, Tambuyzer L, et al
AIDS Res Hum Retroviruses
. 2011 May 10
Abstract

Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.
Córdova E, Loiza E, Porteiro N, Mingrone H.
Enferm Infecc Microbiol Clin. 2011 May 16.

Abstract

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
Charpentier C, Roquebert B, Colin C, et al
AIDS
. 2010 Aug 26
Abstract

Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA)dagger.
Di Vincenzo P, Rusconi S, Adorni F, et al

HIV Med
. 2010 Mar 8
Abstract

Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials.
Peeters M, Vingerhoets J, Tambuyzer L, et al 
AIDS. 2010 Feb 12.
Abstract.|
 

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.
Vingerhoets J, Tambuyzer L, Azijn H,  et al
AIDS
2010 Jan 5.
Abstract.


Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).
Scherrer AU, Hasse B, von Wyl V,  et al 
HIV Med
. 2009 Sep 1

Abstract

HIV-1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
Xu H, Quan Y, Brenner BG, Bar-Magen T, et al 
Antimicrob Agents Chemother
. 2009 Aug 24
Abstract

Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples.
Kagan RM, Sista P, Pattery T, et al 
AIDS
. 2009 May 25
Abstract

Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.
Cotte L, Trabaud MA, Tardy JC, et al 
J Med Virol
. 2009 Feb 23;81(4):672-677
Abstract
 

Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.
Poveda E, de Mendoza C, Pattery T, et al

AIDS
. 2008 Nov 12;22(17):2395-8.
Abstract
 
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
Lapadula G, Calabresi A, Castelnuovo F, et al  
Antivir Ther. 2008;13(4):601-5.
Abstract

Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
Llibre JM, Santos JR, Puig T, et al
J Antimicrob Chemother. 2008 Jul 23.

Abstract


Drug/Drug/Herb Interactions
 

 
FULL-TEXT ARTICLE
Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism.
Belkhir L, Elens L, Zech F,  et al

PLoS One
. 2016 Oct 27;11(10):e0165631
Paper

Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.
Kakuda TN, Leopold L, Nijs S,  et al

J Clin Pharmacol
. 2014 May;54(5):563-73.
Abstract

Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
Kakuda TN, Woodfall B, De Marez T,  et al
J Antimicrob Chemother
. 2013 Oct 23.
Abstract

Effects of Etravirine on the Pharmacokinetics of the Integrase Inhibitor S/GSK1265744.
Ford SL, Gould E, Chen S,
et al 
Antimicrob Agents Chemother
. 2012 Oct 31.
Abstract

Pharmacokinetic Interaction between Boceprevir and Etravirine in HIV/HCV Seronegative Volunteers.
Hammond KP, Wolfe P, Burton JR Jr, :
J Acquir Immune Defic Syndr. 2012 Oct 15
Abstract

Herb-Drug Interaction between Echinacea purpurea and Etravirine in HIV-Infected Patients.
Moltó J, Valle M, Miranda C, et al
Antimicrob Agents Chemother. 2012 Aug 6
Abstract

Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
Lê MP, Solas C, Garraffo R, Gagnieu MC,  et al
J Antimicrob Chemother
. 2012 Jul 6.
Abstract

Pharmacokinetics and Short-Term Safety of Etravirine in Combination With Fluconazole or Voriconazole in HIV-Negative Volunteers.
Kakuda TN, Van Solingen-Ristea R, Aharchi F,

J Clin Pharmacol
. 2012 Feb 10.

Abstract

The Effect of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir.
Song I, Borland J, Min S, et al  
Antimicrob Agents Chemother
. 2011 May
Abstract

Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone.
Schöller-Gyüre M, Kakuda TN, Woodfall B, et al 
Contraception. 2009 Jul;80(1):44-52.
Abstract

Minimal Pharmacokinetic Interaction Between the HIV Non-Nucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects.
Anderson MS, Kakuda TN, Hanley W, et al   

Antimicrob Agents Chemother.
2008 Oct 6.
Abstract
 

A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in
HIV-volunteers.
Schöller-Gyüre M, Kakuda TN, De Smedt G, et al
Br J Clin Pharmacol. 2008 May 19
Abstract

Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of Methadone and TMC125 in HIV-Negative Volunteers. 
Schöller-Gyüre M, van den Brink W, et al
J Clin Pharmacol. 2008 Jan 14
Abstract

Diagnostics/Monitoring
 

 
Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
Parsons TL, Marzinke MA.

J Pharm Biomed Anal
. 2016 Sep 4;131:333-344.
Abstract

Poor performance of laboratories assaying newly developed antiretroviral agents: results for darunavir, etravirine and raltegravir from The International Quality Control Program for Therapeutic Drug Monitoring of Antiretroviral Drugs in Human Plasma/Serum.
Burger D, Krens S, Robijns K, et al
Ther Drug Monit
. 2014 May 9
Abstract

Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
Geretti AM, Conibear T, Hill A,  et al
J Antimicrob Chemother. 2013 Nov 27
Abstract

Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems.
Vingerhoets J, Nijs S, Tambuyzer L,
Antivir Ther. 2012 Aug 6.
Abstract

Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.
Ter Heine R, Mulder JW, van Gorp EC, et al
Bioanalysis
. 2011 May;3(10):1093-7
Abstract

A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.
Fayet A, Béguin A, Zanolari B, Cruchon S, et al

J Chromatogr B Analyt Technol Biomed Life Sci
. 2009 Feb 28
Abstract

Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry.
Ter Heine R, Rosing H, van Gorp EC, et al
J Pharm Biomed Anal
. 2008 Nov 5.

Abstract


Efficacy
 

 

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.
Arathoon E, Bhorat A, Silaghi R,  et al

SAGE Open Med
. 2017 Jan 18;5:2050312116686482
.
Abstract

FULL-TEXT ARTICLE
Effectiveness of etravirine-based therapy for treatment-experienced HIV-infected patients.
Huerta García G, Mata-Marín JA,  et al

J Infect Dev Ctries
. 2016 Jun 30;10(6):605-11
Paper

FULL-TEXT ARTICLE
Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study
Teeranaipong P, Sirivichayakul S, Mekprasan S,
PLoS One
. 2016 Apr 27;11(4):e0154221.
Paper

Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.
Allavena C, Katlama C, Cotte L, et al 
Infect Dis (Lond). 2016 Jan 13:1-7.
Abstract

Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.
Vingerhoets J, Calvez V, Flandre P, et al 

HIV Med
. 2015 May;16(5):297-306.
Abstract

The Intelence and Prezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
Ruane P, Brinson C, Ramgopal M, et al

HIV Med
. 2015 Jan 14.
Abstract

Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.
Vingerhoets J, Calvez V, Flandre P, et al

HIV Med
. 2015 Jan 14
Abstract

Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.
Casado JL, Bañón S, Rodriguez MA,  et al

Antiviral Res
. 2015 Jan;113:103-6.

Abstract

FULL-TEXT ARTICLE
Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population.
López-Cortés LF, Viciana P, Girón-González JA,  et al

PLoS One
. 2014 May 16;9(5):e97262
Paper

FULL-TEXT ARTICLE
Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients
Receiving a Protease Inhibitor-Containing Regimen. Etraswitch Study.

Echeverría P, Bonjoch A, Puig J,  et al

PLoS One
. 2014 Feb 4;9(2):e84676.
Paper

Etravirine in clinical practice: Experience in 151 non-naïve patients
Valencia Ortega ME, Moreno Celda V, Ramírez-Olivencia G, Martín Carbonero L.
Enferm Infecc Microbiol Clin
. 2013 Dec;31(10):669-
7
Abstract

The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
Kakuda TN, Van Solingen-Ristea RM, Onkelinx J,  et al
J Clin Pharmacol. 2013 Oct 25.
Abstract

Etravirine in clinical practice: Experience in 151 non-naïve patients.
Valencia Ortega ME, Moreno Celda V, et al
Enferm Infecc Microbiol Clin
. 2013 Oct 12
Abstract

Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.
Monteiro P, Perez I, Laguno M,  et al
J Antimicrob Chemother
. 2013 Oct 14.
Abstract

Etravirine for the treatment of HIV/AIDS.
Schrijvers R.
Expert Opin Pharmacother. 2013 Apr 8
Abstract

Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network.
Gebo K, Voss C, Mrus J, HIV Research Network
AIDS Res Treat. 2013;2013:492831
Abstract

Lipid-Lowering Effect and Efficacy After Switching to Etravirine in HIV-Infected Patients With Intolerance to Suppressive HAART.
Casado JL, de Los Santos I, Del Palacio M, et al
HIV Clin Trials
. 2013 Jan 1;14(1):1-9.
Abstract

Etravirine in protease inhibitor-free antiretroviral combination therapies.
Schuelter E, Luebke N, Jensen B,
J Int AIDS
Soc
. 2012 Nov 11;15(6):18260.
Abstract

Genotypic susceptibility to etravirine-assessment in a population of NNRTI-experienced patients.
Piñeiro C, Xerinda S, Figueiredo C,  et al
J Int AIDS
Soc
. 2012 Nov 11;
Abstract

First line etravirine use in naïve patients: real-world data in a UK centre.
Ward C, Shaw J, Ahmad S.
J Int AIDS
Soc
. 2012 Nov 11;15(6):18245.
Abstract

Etravirine: A Review of its Use in the Management of Treatment-Experienced Patients with HIV-1 Infection.
Croxtall JD.
Drugs
. 2012 Apr 16;72(6):847-69.
Abstract

Week 96 Outcomes of Patients With Less Treatment Experience Versus More Treatment Experience Receiving Etravirine in the DUET Trials.
Anderson D, Demasi R, Delaitsch L,  et a
l
Curr HIV Res
. 2012 Apr 11.
Abstract

Efficacy and Safety Outcomes Among Treatment-Experienced Men and Women Treated with  Etravirine in GRACE (Gender, Race AND Clinical Experience).
Hodder S, Jayaweera D, Mrus JM,  et al
AIDS Res Hum Retroviruses
. 2011 Dec 29.
Abstract

Use of Maraviroc-, Raltegravir-, and Etravirine-Containing Regimens in Treatment-Experienced Patients: A Case-Series Study.
Youngblood C, Sayana S, Khanlou H.
J Int Assoc Physicians AIDS Care (Chic). 2011 Mar 23
Abstract

High effectiveness of etravirine in routine clinical practice in treatment-experienced HIV-1-infected patients.
Santos JR, Llibre JM, Domingo P,  et al

AIDS Res Hum Retroviruses
. 2010 Nov 30.

Abstract

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
Katlama C, Clotet B, Mills A, et al

Antivir Ther
. 2010;15(7):1045-52
Abstract

Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009;23:2289 300.
Hull MW, Montaner JS.
 
Expert Opin Pharmacother
. 2010 Apr 3
Abstract

Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early |Access Program in the United States.
Towner W, Lalezari J, Sension MG, et al

J Acquir Immune Defic Syndr
. 2010 Feb 3
Abstract


HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
Florence E, De Wit S, Castagna A,  et al
Int J STD AIDS. 2010 Jan 13.
Abstract

Role of etravirine in combination antiretroviral therapy.
Domingo P.
Enferm Infecc Microbiol Clin
. 2009 Dec;27S2:46-51.
Abstract
 
Etravirine in first-line therapy
Garcés PA, Tena EV.
 
Enfer
m Infecc Microbiol Clin. 2009 Dec;27S2:12-20
Abstract

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Katlama C, Haubrich R, Lalezari J, et al
 
AIDS
. 2009 Aug 25.
Abstract

Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers.
Boffito M, Jackson A, Lamorde M,  et al  
J Acquir Immune Defic Syndr
. 2009 Jul 17|
Abstract

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.
Rosso R, Bernardini C, Bruzzone B, et al 
Eur J Med Res
. 2009 Mar 17;14(3):136-8.
Abstract

Efficacy of Etravirine for Treatment of Acute HIV Meningoencephalitis.
Couzigou C, Seang S, Morand-Joubert L, et al 
Clin Infect Dis
. 2009 Feb 1
Abstract
 

Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients:
48-week results of a phase IIb trial.
Cohen CJ, Berger DS, Blick G, et al 
AIDS. 2008 Dec 24
Abstract
 
Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.
Sungkanuparph S, Manosuthi W, Kiertiburanakul S,et al

Curr HIV Res. 2008 Sep;6(5):474-6
Abstract
 
Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase
inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K, Pedro R, Latiff G, et al
 
HIV Med.
2008 Sep 14.
Abstract
 
Safety, Tolerability, and Preliminary Efficacy of 48 Weeks of Etravirine Therapy in a Phase IIb Dose-Ranging Study Involving Treatment-Experienced Patients with HIV-1 Infection.
Montaner J, Yeni P, Clumeck NN, et al

Clin Infect Dis.
2008 Sep 2.
Abstract
 
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lazzarin A, Campbell T, Clotet B, et al
 
Lancet
. 2007 Jul 7;370(9581):39-48.
Abstract
 
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Madruga JV, Cahn P, Grinsztejn B, et al

Lancet. 2007 Jul 7;370(9581):29-38.
Abstract

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
The TMC125-C223 Writing Group.
AIDS. 2007 Mar 30;21(6):F1-F10.
Abstract

TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
Sankatsing SU, Weverling GJ, Peeters M, et al
AIDS. 2003 Dec 5;17(18):2623-7
Abstract

A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.
Gruzdev B, Rakhmanova A, Doubovskaya E, et al
AIDS. 2003 Nov 21;17(17):2487-94.
Abstract

Adverse Events
 

 
Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.
Casado JL, Mena A, Bañón S, et al
HIV Med. 2015 Jun 30
Abstract

Allergic hypersensitivity to antiretroviral drugs: etravirine, raltegravir and darunavir.
Sánchez-Olivas MA, Valencia-Zavala MP, Vega-Robledo GB,  et al

Rev Alerg Mex
. 2015 Apr-Jun;62(2):142-148
Abstract

Liver Toxicity in HIV-Infected Patients Receiving Novel Second-Generation Nonnucleoside Reverse Transcriptase Inhibitors Etravirine and Rilpivirine.
Casado JL.
AIDS Rev. 2013 Jul-Sep;15(3):139-45.
Abstract

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
Nelson M, Stellbrink HJ, Podzamczer D, et al

AIDS
. 2010 Dec 9.

Abstract


Therapeutic Strategies
 

 
Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.
Ciaffi L, Cavassini M, Genne D,
 et al
Eur J Clin Invest
. 2015 May 20.

Abstract

A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance.
Bañón S, Moreno A, Quereda C,  et al

J Int AIDS Soc
. 2014 Nov 2;17(4(Suppl 3)):19804
Abstract

Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma.
Kurz M, Stoeckle M, Krasniqi F,  et al

Int J STD AIDS
. 2014 May 8.
Abstract

Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.
Nozza S, Galli L, Bigoloni A, Gianotti N, et al
New Microbiol
. 2014 Apr;37(2):145-51

Abstract

FULL-TEXT ARTICLE
Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials.
Nelson M, Hill A, van Delft Y, Moecklinghoff C
.
AIDS Res Treat
. 2
014;2014:636584.
Paper

Immune activation throughout a boosted darunavir monotherapy simplification strategy.
Benmarzouk-Hidalgo OJ, Torres-Cornejo A, Gutiérrez-Valencia A, et al

Clin Microbiol Infect
. 2013 Dec 26
Abstract

Does Once-Daily Etravirine Have a Role in the Management of HIV-1 Infection?
McNicholl IR
Drugs
. 2013 Feb 19.
Abstract

Etravirine with 2 NRTIs: an effective switch option for ARV simplification and side effect management.
Smith G, Brunetta J, Loutfy M, Crouzat F, et al
J Int AIDS Soc
. 2012 Nov 11;15(6):18288.
Abstract

Switching to an etravirine regimen in virologically suppressed patients with previous virological failures and presence of resistance mutations.
Blanco J, Casado J, González-Cordón A, Martinez E, et al
J Int AIDS Soc
. 2012 Nov 11;15(6):18379
Abstract

Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?
Estebanez M, Stella-Ascariz N, Ruiz-Carrascoso G, et al
AIDS. 2013 Jan 2;27(1):141-4.
Abstract

Switch From Etravirine Twice Daily to Once Daily in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant HIV-Infected Patients With Suppressed Viremia: The Monetra Study.
Schneider L, Ktorza N, Fourati S,  et al
HIV Clin Trials. 2012 Sep-Oct;13(5):284-8
Abstract

Etravirine: A Review of its Use in the Management of Treatment-Experienced Patients with HIV-1 Infection.
Croxtall JD.
Drugs. 2012 Apr 16;72(6):847-69.
Abstract

FULL-TEXT PDF ARTICLE
Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

Tommasi C, Bellagamba R, Tempestilli M, et al

Malar J
. 2011 May 21;10(1):141.
Paper

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
Waters L, Fisher M, Winston A,   et al

AIDS
. 2010 Nov 19
Abstract

A 48-Week Pilot Study Switching Suppressed Patients to Darunavir/Ritonavir and Etravirine from Enfuvirtide, Protease Inhibitor(s), and Non-nucleoside Reverse Transcriptase Inhibitor(s).
Ruane P, Alas B, Ryan R, et al
AIDS Res Hum Retroviruses. 2010 Nov;26(11):1215-1219.
Abstract

Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.
Nozza S, Galli L, Visco F, Soria A,  et al
AIDS. 2010 Feb 11

Abstract


Drug Comparison Studies
 

 
Etravirine-based antiretroviral therapy in HIV/hepatitis C virus coinfected advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir.
Ramirez ML, Vargas FX, González-Garcia J, et al
AIDS
. 2014 Oct 23;28(16):2487-9.
Abstract

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized,
double-blind SENSE trial.
Fätkenheuer G, Duvivier C, Rieger A,  et al

J Antimicrob Chemother
. 2011 Dec 29.
Abstract

Phase 2 double-blind, randomised trial of etravirine versus efavirenz in treatment-naïve patients: 48 week results.
Gazzard B, Duvivier C, Zagler C,  et al

AIDS
. 2011 Aug 30.

Abstract


Economics
 

 
Cost-effectiveness of Combination Therapy With Etravirine in Treatment-Experienced Adults With HIV-1 Infection in Canada.
Mauskopf J, Brogan AJ, Talbird SE, Martin S
AIDS. 2011 Nov 14.

Abstract


Etravirine Main Page Main New/Newsworthy  Home Page      

Etravirine Journal Citations